Webinar: SpringWorks Therapeutics and the ReNeu Trial for NF1-Related Plexiform Neurofibromas
Wednesday, July 14th @ 7PM CST
The NF Network is pleased to announce that it will be hosting a webinar with SpringWorks Therapeutics on Wednesday, July 14th at 8:00 pm EST / 5:00pm PST. SpringWorks is a biopharmaceutical company whose mission is to develop life-changing medicines for patients with severe rare diseases and cancer. They are conducting a Phase 2b clinical trial (the “ReNeu trial”) with their investigational MEK inhibitor called mirdametinib in children and adults with NF1-associated plexiform neurofibromas (NF1-PN). During the webinar, people will learn about the differences between NF1 and NF2, what plexiform neurofibromas are, and more about mirdametinib and the ReNeu trial. Speakers include Dr. Mary Smith, Chief Development Officer of SpringWorks and members of her team who are responsible for helping to conduct the ReNeu trial.
Dr. Mary Smith is responsible for designing and running the clinical development programs. Prior to joining SpringWorks Therapeutics, Mary was the Executive Vice President of Gene Therapy at Bamboo Therapeutics, a wholly owned subsidiary of Pfizer where she led several key gene transfer programs for rare genetic diseases. Prior to joining Bamboo, Mary was Vice President of product development at United Therapeutics, with responsibility for biological development in oncology, as well as regenerative medicine and virology. Mary earned a Ph.D. in microbiology/immunology from the University of New Hampshire and received her post-doctoral training at Emory University.
Registration for this free event is open now! We look forward to hosting this important event with SpringWorks, who is a valuable partner to the NF Network. Hope that you can join us on July 14th.
